MBRX · Moleculin Biotech, Inc. · Investor Relations
$7.74
-0.19 (-2.40%)
At close · Nov 20
Return incl. dividend (before tax)
Q1 2025 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
Market Cap
$8.22M
Shares
1.06M
Volume · Nov 20
49.56K
Avg daily vol (24 sessions)
44.57K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
Past events
| Date | Event | Type |
|---|---|---|
| 2026-10-14 | 2026 Maxim Growth Summit | Conference |
| 2026-09-25 | Turning cold pancreatic tumors hot: Antitumor activity of Annamycin is partially mediated by CD8+ T cell cytotoxicity | Event |
| 2026-09-14 | Organotropism-guided exploration of anticancer properties of Annamycin (naxtarubicin), a potent topoisomerase II targeting agent | Event |
| 2026-09-11 | Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand | Conference |
| 2026-09-09 | Antitumor activity of ANNAMYCIN, a highly effective lipophilic DNA-binding drug: Impact of its organotropism | Event |
| 2026-05-29 | Poster Presentation, 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Presentation |
| 2026-03-24 | 38th Annual ROTH Conference Fireside Chat | Conference |
| 2026-02-11 | Corporate Connect Webinar Series hosted by Webull Financial | Event |
| 2025-10-30 | The 14th Annual Acute Leukemia Meeting | Event |
Source: https://moleculin.com/investors/
Key facts
CIK
1659617
CUSIP
60855D507
13F (30d)
32 filings
22 filers
Visit website
Investor relations